Cannabis, otherwise known as marijuana, may be recommended as an add-on therapy for MS patients. One such treatment being investigated is Sativex, an oral spray that contains cannabis extracts, to improve spasticity in MS patients.
Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticity in adult multiple sclerosis (MS) patients who failed to respond to other anti-spastic treatments, a real-world study from Belgium reports. Overall,…
Read moreCanadian researchers are testing mice to see if cannabinoid oil products — a common medical marijuana treatment — could help alleviate the neuropathic pain that often afflicts patients with multiple sclerosis (MS). The preclinical study, “Identifying the molecular mechanisms involved…
Ninety-five percent of multiple sclerosis (MS) patients believe medical marijuana should be a treatment option, according to a GeneFo online survey. The survey also showed that almost 73 percent had tried it, even though about half said they hadn’t received information…
Most Irish general practitioners (GPs) are against decriminalizing cannabis use, but many, especially those over age 50, say it can be useful for treating multiple sclerosis (MS) and other medical conditions, according to a recent survey. The results are detailed in…
Certain cannabinoids reduce spasticity symptoms in multiple sclerosis (MS) patients, according to a report from The National Academies of Sciences, Engineering, and Medicine that scrutinized published research about the benefits and hazards of cannabis and cannabinoid use. Cannabinoids also show proven effect in other areas that…
BAS Research, recently granted California’s first medicinal marijuana manufacturing and research license, is teaming with Montel Williams’ LenitivLabs startup to begin developing, producing and marketing medical-grade cannabis products. BAS’ goal is to replace the social stigma associated with cannabis by…
Voters in four U.S. states on Nov. 8 chose to legalize the recreational use of marijuana, and those in three other states approved the medicinal use of cannabis — all gains for pharmaceutical and other companies designing cannabis-based therapies for people…
Medical Marijuana announced that Axim Biotechnologies, a cannabinoid-based product developer in which it owns a strategic interest, has released a product pipeline chart highlighting development timelines for its cannabinoid-based therapeutics, including those for multiple sclerosis (MS) patients. The chart illustrates the…
Columbia Care announced the launch of its line of pills for medical marijuana — calling it the first controlled-dose, pharmaceutical-quality and solid-fill medical cannabinoid capsule available to people with prescriptions for medical marijuana use in the U.S. The New…
CannaCure Florida, a patient-focused producer of medical cannabis and related products, will host physicians and medical professionals for a peer-to-peer medical cannabis educational conference Nov. 18 in Tampa to provide guidance for incorporating medical cannabis into traditional medical practices. The event…
Abide Therapeutics announced that Celgene has opted to obtain the rights, outside of the United States, to ABX-1431, Abide’s endocannabinoid system modulator being developed to treat neurological diseases, including multiple sclerosis (MS), by reproducing within the body the…
MS sidelined his dreams of playing pro football, so Tyler called an audible! Listen in as Jenn chats with Tyler Campbell, son of Football Hall of Fame legend Earl Campbell.
Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.
Get regular updates to your inbox.